本文章的学术内容和语言评估
本文章的CrossCheck查重和Google搜索
本文章的学术规范
本文章的引用
本文章的通讯作者
本文章的研究领域
本文章的类型
本文章的开放获取政策
本文章的Google引用次数
本文章的点击和下载次数
- 本文章浏览次数 (5578)
All Articles published online
|
Publishing Process of This Article
|
Feb 14, 2024 (publication date) through Jun 19, 2025
本文章的被引频次
本文章的期刊信息
出版物名称
World Journal of Gastroenterology
ISSN
1007-9327
本文章的出版商
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Seddik H, Benass J, Berrag S, Sair A, Berraida R, Boutallaka H. Optimized sequential therapy vs 10- and 14-d concomitant therapy for eradicating Helicobacter pylori: A randomized clinical trial. World J Gastroenterol 2024; 30(6): 556-564 [PMID: 38463026 DOI: 10.3748/wjg.v30.i6.556] |
|---|---|
| URL: | https://www.wjgnet.com/1009-3079/full/v30/i6/556.htm |
| 编号 | Citing Articles |
| 1 |
Tianlian Yan, Jinghua Wang, Renke Zhu, Dan Ma, Jianguo Gao, Jiewei Wang, Ye Chen, Kefang Sun, Qing Gu, Lan Li. Vonoprazan improves the efficacy of bismuth quadruple therapy containing doxycycline and metronidazole as first-line Helicobacter pylori treatment in penicillin-allergic patients: a randomized controlled trial. Journal of Antimicrobial Chemotherapy 2025; 80(4): 927 doi: 10.1093/jac/dkae467
|
| 2 |
Jad Chidiac, Reine-Marie Kahwaji, Souheil Hallit, Yara Yazbeck, Bassem Akiki, Charbel Yazbeck. A Randomized, Prospective and Crossover Study, Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Population. Current Therapeutic Research 2025; 102: 100791 doi: 10.1016/j.curtheres.2025.100791
|